Chimeric antigen receptor(CAR)T-cell therapy that targets B-cell maturation antigen(BCMA)have great potentials in autoimmune diseases and could be novel therapeutics for relapsed/refractory neuromyelitis optica spectr...Chimeric antigen receptor(CAR)T-cell therapy that targets B-cell maturation antigen(BCMA)have great potentials in autoimmune diseases and could be novel therapeutics for relapsed/refractory neuromyelitis optica spectrum disorder(NMOSD).To evaluate the safety and efficacy of the CT103A,a self-developed BCMA-targeting CAR construct against BCMA,in patients with AQP4-IgG seropositive NMOSD,an ongoing,investigator-initiated,open-label,single-arm,phase 1 clinical trial is conducted at our center.In total,12 patients were administered with a CAR-BCMA infusion.Ten of the 12 patients dosed were women(83.3%),with a median age of 49.5 years(range,30-67).were The most common events of grade 3 or higher were hematologic toxic effects.Seven patients(58%)developed infections,but no grade 4 infections occurred.Cytokine release syndrome was reported in all patients with only events of grade 1 or 2 observed.During the follow-up of a median 5.5 months,11 patients had no relapse;all patients generally reported improvement in disabilities and quality-of-life outcomes;11 patients’AQP-4 antibodies in serum showed a downward trend by the cutoff date.CAR T-cell expansion was associated with responses,and persisted more than 6 months post-infusion in 17%of the patients.In summary,CAR T-cell therapy shows a manageable safety profile and therapeutic potentials for patients with relapsed/refractory AQP4-IgG seropositive NMOSD.Another expansion phase is currently underway to determine the safety and efficacy of CAR T-BCMA infusion in patients with other neuro-inflammatory diseases.展开更多
Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals;however,the prognosis remains poor.The BCMA antigen is highly expressed in myeloma cells,thus representing a ta...Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals;however,the prognosis remains poor.The BCMA antigen is highly expressed in myeloma cells,thus representing a target for novel therapies.Several agents that target BCMA through different mechanisms,including bispecific T cell engagers drug conjugated to antibody and CAR-T cells,are now available or under development.Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy.This review will discuss the recent development of anti-BCMA targeted treatments in myeloma,with a special focus on currently available agents.展开更多
本文最初发表于2019年Lancet Hematology,文章题录为:Yan Z,Cao J,Cheng H,et al.A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma:a single-arm,phase 2 t...本文最初发表于2019年Lancet Hematology,文章题录为:Yan Z,Cao J,Cheng H,et al.A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma:a single-arm,phase 2 trial[J].Lancet Haematol,2019,6:e521-e529。该研究表明,联合输注人源化抗CD19及鼠源抗BCMA CAR-T细胞在治疗复发/难治多发性骨髓瘤(R/R MM)显示出了肯定的疗效,且其安全性良好。这是一个有前景的治疗策略,值得临床试用。这一研究结果为R/R MM的细胞免疫治疗提供了新的思路。展开更多
Objective We observed and compared the differences in immune reconstruction between single-infusion anti-B-cell maturation antigen(BCMA),chimeric antigen receptor T cells(CAR-T),and combined infusion of anti-CD19 CAR-...Objective We observed and compared the differences in immune reconstruction between single-infusion anti-B-cell maturation antigen(BCMA),chimeric antigen receptor T cells(CAR-T),and combined infusion of anti-CD19 CAR-T cells in the treatment of recurrent/refractory multiple myeloma(RRMM).Methods Sixty-one patients with RRMM who underwent CAR-T cell therapy in our hospital from June 2017 to December 2020 were selected.Among them,26 patients received anti-BCMA target,and 35 patients received anti-BCMA combined with anti-CD19 target.展开更多
文摘Chimeric antigen receptor(CAR)T-cell therapy that targets B-cell maturation antigen(BCMA)have great potentials in autoimmune diseases and could be novel therapeutics for relapsed/refractory neuromyelitis optica spectrum disorder(NMOSD).To evaluate the safety and efficacy of the CT103A,a self-developed BCMA-targeting CAR construct against BCMA,in patients with AQP4-IgG seropositive NMOSD,an ongoing,investigator-initiated,open-label,single-arm,phase 1 clinical trial is conducted at our center.In total,12 patients were administered with a CAR-BCMA infusion.Ten of the 12 patients dosed were women(83.3%),with a median age of 49.5 years(range,30-67).were The most common events of grade 3 or higher were hematologic toxic effects.Seven patients(58%)developed infections,but no grade 4 infections occurred.Cytokine release syndrome was reported in all patients with only events of grade 1 or 2 observed.During the follow-up of a median 5.5 months,11 patients had no relapse;all patients generally reported improvement in disabilities and quality-of-life outcomes;11 patients’AQP-4 antibodies in serum showed a downward trend by the cutoff date.CAR T-cell expansion was associated with responses,and persisted more than 6 months post-infusion in 17%of the patients.In summary,CAR T-cell therapy shows a manageable safety profile and therapeutic potentials for patients with relapsed/refractory AQP4-IgG seropositive NMOSD.Another expansion phase is currently underway to determine the safety and efficacy of CAR T-BCMA infusion in patients with other neuro-inflammatory diseases.
文摘Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals;however,the prognosis remains poor.The BCMA antigen is highly expressed in myeloma cells,thus representing a target for novel therapies.Several agents that target BCMA through different mechanisms,including bispecific T cell engagers drug conjugated to antibody and CAR-T cells,are now available or under development.Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy.This review will discuss the recent development of anti-BCMA targeted treatments in myeloma,with a special focus on currently available agents.
文摘本文最初发表于2019年Lancet Hematology,文章题录为:Yan Z,Cao J,Cheng H,et al.A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma:a single-arm,phase 2 trial[J].Lancet Haematol,2019,6:e521-e529。该研究表明,联合输注人源化抗CD19及鼠源抗BCMA CAR-T细胞在治疗复发/难治多发性骨髓瘤(R/R MM)显示出了肯定的疗效,且其安全性良好。这是一个有前景的治疗策略,值得临床试用。这一研究结果为R/R MM的细胞免疫治疗提供了新的思路。
文摘Objective We observed and compared the differences in immune reconstruction between single-infusion anti-B-cell maturation antigen(BCMA),chimeric antigen receptor T cells(CAR-T),and combined infusion of anti-CD19 CAR-T cells in the treatment of recurrent/refractory multiple myeloma(RRMM).Methods Sixty-one patients with RRMM who underwent CAR-T cell therapy in our hospital from June 2017 to December 2020 were selected.Among them,26 patients received anti-BCMA target,and 35 patients received anti-BCMA combined with anti-CD19 target.
